Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on April 16, 2013. The report details the completion of the distribution of 100% of the outstanding common stock of AbbVie Inc. to Abbott's shareholders on January 1, 2013. AbbVie is now an independent public company trading under the symbol "ABBV" on the New York Stock Exchange.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains unaudited non-GAAP financial information for 2012. This exhibit presents the AbbVie business as a discontinued operation and provides a historical baseline for Abbott's standalone continuing operations, excluding specified items such as acquisition-related costs, asset impairments, and separation costs.
Material Changes
The primary material change is the corporate separation of AbbVie. Consequently, Abbott's financial presentation has shifted to reflect standalone continuing operations. The filing notes that future results will be evaluated against a historical baseline that excludes the AbbVie business and specific one-time costs.
Guidance, Outlook, and Management Commentary
Management states that the financial information provided is for informational purposes only and does not project future financial performance or cost structure. Abbott utilizes non-GAAP measures to adjust for unusual or unpredictable factors, including separation costs, litigation reserves, and intangible amortization, to provide visibility on ongoing business performance. Investors are cautioned to consider these non-GAAP measures in addition to, not as a substitute for, GAAP measures.
Important Facts for Investor Verification
- Verify the specific non-GAAP financial figures and reconciliations to GAAP in Exhibit 99.1, as they are not detailed in the main text of this filing.
- Confirm the impact of the AbbVie spin-off on Abbott's standalone revenue and earnings by reviewing the 2012 Form 10-K/A referenced in the filing.
- Assess the magnitude of "specified items" excluded from non-GAAP results, such as separation costs and asset impairments, to understand the true operating performance.
- Note that the filing explicitly states it does not contain forward-looking projections for future periods.